Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an

Paco E Bravo1, Hong-Chang Luo2, Iraklis Pozios2

  • 1Department of Cardiology, University of Washington, 1959 NE Pacific Street, PO Box 356422, Seattle, WA 98195, USA Johns Hopkins Medical Institutions, Baltimore, MD, USA pbravo@uw.edu.

Insights

Hypertrophic cardiomyopathy (HCM) patients with right ventricular insertion point (RVIP) late gadolinium enhancement (LGE) show intermediate cardiac function and structure. This RVIP LGE phenotype is distinct from no LGE or left ventricular intramural LGE.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Cardiovascular Disease

Background:

  • Hypertrophic cardiomyopathy (HCM) is a complex genetic heart disease.
  • Late gadolinium enhancement (LGE) on cardiac MRI is a key imaging biomarker in HCM.
  • The distribution of LGE may correlate with disease severity and phenotype.

Purpose of the Study:

  • To compare phenotypic characteristics of HCM patients with LGE confined to right ventricular insertion points (RVIP) versus those with no LGE or left ventricular (LV) intramural LGE.
  • To investigate the potential of RVIP LGE as an intermediate phenotype in HCM.

Main Methods:

  • Cardiac MRI for LGE quantification and LV thickness measurement in 62 HCM patients.
  • Classification into three groups: no-LGE (n=18), LGE-RVIP (n=19), and intramural LGE (n=25).
  • N-13 ammonia PET for myocardial blood flow (MBF) and myocardial flow reserve (MFR) assessment; echocardiography for LV longitudinal strain.

Main Results:

  • LGE extent and LV thickness were significantly higher in the intramural LGE group, intermediate in the LGE-RVIP group, and lowest in the no-LGE group.
  • Myocardial blood flow (MBF), myocardial flow reserve (MFR), and LV longitudinal strain were significantly reduced in the intramural LGE group, intermediate in the LGE-RVIP group, and highest in the no-LGE group.
  • These findings indicate distinct functional and structural differences across the LGE patterns.

Conclusions:

  • HCM patients with LGE restricted to RVIP represent an intermediate phenotype.
  • This intermediate phenotype lies between patients with no LGE and those with LV intramural LGE.
  • RVIP LGE may signify a distinct stage in HCM progression, identifiable through advanced cardiac imaging.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
754
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
877
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
786
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
966
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
840
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
1.1K